Update on the Targeted Therapy of Melanoma

Relief of Profound Feedback Inhibition of Mitogenic Signaling by RAF Inhibitors Attenuates Their Activity in BRAFV600E Melanomas

(2012) Piro Lito et al.   CANCER CELL

The HSP90 Inhibitor XL888 Overcomes BRAF Inhibitor Resistance Mediated through Diverse Mechanisms

(2012) K. H. T. Paraiso et al.   CLINICAL CANCER RESEARCH

Sunitinib Therapy for Melanoma Patients withKITMutations

(2012) David R. Minor et al.   CLINICAL CANCER RESEARCH

The Activation of MAPK in Melanoma Cells Resistant to BRAF Inhibition Promotes PD-L1 Expression That Is Reversible by MEK and PI3K Inhibition

(2012) X. Jiang et al.   CLINICAL CANCER RESEARCH

Atypical Melanocytic Proliferations and New Primary Melanomas in Patients With Advanced Melanoma Undergoing SelectiveBRAFInhibition

(2012) Lisa Zimmer et al.   JOURNAL OF CLINICAL ONCOLOGY

Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial

(2012) Gerald S Falchook et al.   LANCET

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

(2012) Axel Hauschild et al.   LANCET

Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial

(2012) Gerald S Falchook et al.   LANCET ONCOLOGY

Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial

(2012) Jeffrey R Infante et al.   LANCET ONCOLOGY

Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial

(2012) Georgina V Long et al.   LANCET ONCOLOGY

Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion

(2012) Ravid Straussman et al.   NATURE

Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors

(2012) Timothy R. Wilson et al.   NATURE

Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma

(2012) Lawrence N Kwong et al.   NATURE MEDICINE

Progression of RAS-Mutant Leukemia during RAF Inhibitor Treatment

(2012) Margaret K. Callahan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

(2012) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib

(2012) Jeffrey A. Sosman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma

(2012) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

RASMutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors

(2012) Fei Su et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

MAP kinase signaling and inhibition in melanoma

(2012) R J Sullivan et al.   ONCOGENE

Prevalence of germlineBAP1mutation in a population-based sample of uveal melanoma cases

(2012) Lauren G. Aoude et al.   Pigment Cell & Melanoma Research

Routine Multiplex Mutational Profiling of Melanomas Enables Enrollment in Genotype-Driven Therapeutic Trials

(2012) Christine M. Lovly et al.   PLoS One

Elucidating Distinct Roles for NF1 in Melanomagenesis

(2012) Ophélia Maertens et al.   Cancer Discovery

BRAF L597 Mutations in Melanoma Are Associated with Sensitivity to MEK Inhibitors

(2012) Kimberly Brown Dahlman et al.   Cancer Discovery

NRAS mutation status is an independent prognostic factor in metastatic melanoma

(2011) John A. Jakob et al.   CANCER

Multicenter, Phase II Study of Axitinib, a Selective Second-Generation Inhibitor of Vascular Endothelial Growth Factor Receptors 1, 2, and 3, in Patients with Metastatic Melanoma

(2011) J. Fruehauf et al.   CLINICAL CANCER RESEARCH

Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma

(2011) James S. Wilmott et al.   CLINICAL CANCER RESEARCH

Phase II, Open-Label, Randomized Trial of the MEK1/2 Inhibitor Selumetinib as Monotherapy versus Temozolomide in Patients with Advanced Melanoma

(2011) J. M. Kirkwood et al.   CLINICAL CANCER RESEARCH

KIT as a Therapeutic Target in Metastatic Melanoma

(2011) Richard D. Carvajal   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling

(2011) Nikhil Wagle et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II, Open-Label, Single-Arm Trial of Imatinib Mesylate in Patients With Metastatic Melanoma Harboringc-KitMutation or Amplification

(2011) Jun Guo et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognostic and Clinicopathologic Associations of OncogenicBRAFin Metastatic Melanoma

(2011) Georgina V. Long et al.   JOURNAL OF CLINICAL ONCOLOGY

BEAM: A Randomized Phase II Study Evaluating the Activity of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced Melanoma

(2011) Kevin B. Kim et al.   JOURNAL OF CLINICAL ONCOLOGY

Correlation of NRAS Mutations With Clinical Response to High-dose IL-2 in Patients With Advanced Melanoma

(2011) Richard W. Joseph et al.   JOURNAL OF IMMUNOTHERAPY

Recent trends in cutaneous melanoma incidence and death rates in the United States, 1992-2006

(2011) Ahmedin Jemal et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)

(2011) Poulikos I. Poulikakos et al.   NATURE

Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma

(2011) Sergey I Nikolaev et al.   NATURE GENETICS

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

(2011) Paul B. Chapman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy

(2010) K H T Paraiso et al.   BRITISH JOURNAL OF CANCER

Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT

(2010) D Handolias et al.   BRITISH JOURNAL OF CANCER

A phase 2 trial of dasatinib in advanced melanoma

(2010) Harriet M. Kluger et al.   CANCER

Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K

(2010) Jessie Villanueva et al.   CANCER CELL

RG7204 (PLX4032), a Selective BRAFV600E Inhibitor, Displays Potent Antitumor Activity in Preclinical Melanoma Models

(2010) H. Yang et al.   CANCER RESEARCH

Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032

(2010) Jill C Rubinstein et al.   Journal of Translational Medicine

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

(2010) Georgia Hatzivassiliou et al.   NATURE

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

(2010) Cory M. Johannessen et al.   NATURE

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

(2010) Ramin Nazarian et al.   NATURE

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

(2010) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mutations inGNA11in Uveal Melanoma

(2010) Catherine D. Van Raamsdonk et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mutations in KIT occur at low frequency in melanomas arising from anatomical sites associated with chronic and intermittent sun exposure

(2010) Despina Handolias et al.   Pigment Cell & Melanoma Research

Correlation between KIT expression and KIT mutation in melanoma: a study of 173 cases with emphasis on the acral-lentiginous/mucosal type

(2009) Carlos A Torres-Cabala et al.   MODERN PATHOLOGY

Activity of dasatinib against L576P KIT mutant melanoma: Molecular, cellular, and clinical correlates

(2009) S. E. Woodman et al.   MOLECULAR CANCER THERAPEUTICS

Combined Targeting of BRAF and CRAF or BRAF and PI3K Effector Pathways Is Required for Efficacy in NRAS Mutant Tumors

(2009) Bijay S. Jaiswal et al.   PLoS One

Analysis of c-KIT expression and KIT gene mutation in human mucosal melanomas

(2008) I Satzger et al.   BRITISH JOURNAL OF CANCER

Elevated CRAF as a Potential Mechanism of Acquired Resistance to BRAF Inhibition in Melanoma

(2008) C. Montagut et al.   CANCER RESEARCH

KIT Gene Mutations and Copy Number in Melanoma Subtypes

(2008) C. Beadling et al.   CLINICAL CANCER RESEARCH

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

(2008) J. Tsai et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Complete response of stage IV anal mucosal melanoma expressing KIT Val560Asp to the multikinase inhibitor sorafenib

(2008) Alfonso Quintás-Cardama et al.   Nature clinical practice. Oncology